Anti-Flotillin 2 (C-Terminal) Polyclonal Antibody (CABT-B1717) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page:16

File Type:pdf, Size:1020Kb

Anti-Flotillin 2 (C-Terminal) Polyclonal Antibody (CABT-B1717) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use Anti-Flotillin 2 (C-terminal) polyclonal antibody (CABT-B1717) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Immunogen Synthetic peptide corresponding to the C-terminus of human Flotillin 2. Isotype IgG Source/Host Rabbit Species Reactivity Human, Rat, Mouse Purification Antigen Affinity Purified Conjugate Unconjugated Applications WB, ICC, IHC Epitope C-terminus Molecular Weight ~45 kDa observed. Uncharacterized bands may be observed in some lysate(s). Format Liquid Concentration Please refer to lot specific datasheet. Size 100 µL Buffer 1XPBS, 20% Glycerol (pH7), and 0.025% proclin. Preservative None Storage Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage. BACKGROUND Introduction Flotillin-2 (also known as Epidermal surface antigen, ESA, or Membrane component chromosome 17 surface marker 1) is encoded by the FLOT2 gene (Entrez Gene ID 2319; also 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved known as ECS1, ECS-1, ESA1, M17S1) in human. Flotillin 2 is a caveolae-associated, integral membrane protein that is involved in Caveolae-mediated vesicular trafficking and signal transduction. GENE INFORMATION UniProt ID Q14254 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • Evolutionarily Conserved Intercalated Disc Protein Tmem65 Regulates Cardiac Conduction and Connexin 43 Function
    ARTICLE Received 11 Aug 2014 | Accepted 18 Aug 2015 | Published 25 Sep 2015 DOI: 10.1038/ncomms9391 Evolutionarily conserved intercalated disc protein Tmem65 regulates cardiac conduction and connexin 43 function Parveen Sharma1,*, Cynthia Abbasi1,*, Savo Lazic2, Allen C.T. Teng1, Dingyan Wang1, Nicole Dubois3, Vladimir Ignatchenko4, Victoria Wong5, Jun Liu6, Toshiyuki Araki4, Malte Tiburcy7, Cameron Ackerley8, Wolfram H. Zimmermann7, Robert Hamilton8,11, Yu Sun6, Peter P. Liu9, Gordon Keller3, Igor Stagljar5, Ian C. Scott2,8,11, Thomas Kislinger4,10 & Anthony O. Gramolini1,11 Membrane proteins are crucial to heart function and development. Here we combine cationic silica-bead coating with shotgun proteomics to enrich for and identify plasma membrane-associated proteins from primary mouse neonatal and human fetal ventricular cardiomyocytes. We identify Tmem65 as a cardiac-enriched, intercalated disc protein that increases during development in both mouse and human hearts. Functional analysis of Tmem65 both in vitro using lentiviral shRNA-mediated knockdown in mouse cardiomyocytes and in vivo using morpholino-based knockdown in zebrafish show marked alterations in gap junction function and cardiac morphology. Molecular analyses suggest that Tmem65 interaction with connexin 43 (Cx43) is required for correct localization of Cx43 to the intercalated disc, since Tmem65 deletion results in marked internalization of Cx43, a shorter half-life through increased degradation, and loss of Cx43 function. Our data demonstrate that the membrane protein Tmem65 is an intercalated disc protein that interacts with and functionally regulates ventricular Cx43. 1 Department of Physiology, University of Toronto, Toronto General Hospital Research Institute, Toronto, Ontario, Canada M5G 1L7. 2 Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada M5S 1A8.
    [Show full text]
  • Views for Entrez
    BASIC RESEARCH www.jasn.org Phosphoproteomic Analysis Reveals Regulatory Mechanisms at the Kidney Filtration Barrier †‡ †| Markus M. Rinschen,* Xiongwu Wu,§ Tim König, Trairak Pisitkun,¶ Henning Hagmann,* † † † Caroline Pahmeyer,* Tobias Lamkemeyer, Priyanka Kohli,* Nicole Schnell, †‡ †† ‡‡ Bernhard Schermer,* Stuart Dryer,** Bernard R. Brooks,§ Pedro Beltrao, †‡ Marcus Krueger,§§ Paul T. Brinkkoetter,* and Thomas Benzing* *Department of Internal Medicine II, Center for Molecular Medicine, †Cologne Excellence Cluster on Cellular Stress | Responses in Aging-Associated Diseases, ‡Systems Biology of Ageing Cologne, Institute for Genetics, University of Cologne, Cologne, Germany; §Laboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; ¶Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; **Department of Biology and Biochemistry, University of Houston, Houston, Texas; ††Division of Nephrology, Baylor College of Medicine, Houston, Texas; ‡‡European Molecular Biology Laboratory–European Bioinformatics Institute, Hinxton, Cambridge, United Kingdom; and §§Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany ABSTRACT Diseases of the kidney filtration barrier are a leading cause of ESRD. Most disorders affect the podocytes, polarized cells with a limited capacity for self-renewal that require tightly controlled signaling to maintain their integrity, viability, and function. Here, we provide an atlas of in vivo phosphorylated, glomerulus- expressed
    [Show full text]
  • Everest Antibody
    DATA SHEET Goat anti-Flotillin 2 / FLOT2 (C Term) Antibody Item Number dAP-0498 Target Molecule Principle Name: Flotillin 2 / FLOT2 (C Term); Official Symbol: FLOT2; All Names and Symbols: FLOT2; flotillin 2; reggie-1; ESA; ESA1; M17S1; Flotillin 2 (epidermal surface antigen 1); ECS-1; ECS1; membrane component; chromosome 17; surface marker 1 (35kD protein identified by monoclonal antibody ECS-1); Accession Number (s): NP_004466.2; Human Gene ID(s): 2319; Non-Human GeneID(s): Immunogen SKIPLIKKATGVQV, is from C Terminus Applications Pep ELISA, WB, IHC Species Tested: Human Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied As lyophilized powder of 50ug or 100ug IgG; Reconsititute IgG with 100ul or 200ul sterile DI Water and final product will be formulated as 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing. Peptide ELISA Peptide ELISA: antibody detection limit dilution 1 to 32000. Western Blot Western Blot: Approx 48kDa band observed in Human Brain (Cerebellum), Lung and Testis lysates (calculated MW of 47.1kDa according to NP_004466.2). Recommended concentration: 0.1-0.3µg/ml. IHC Immunohistochemistry: Paraffin embedded Human Tonsil and Kidney. Recommended concentration: 3.75µg/ml. Reference Reference(s): Rajendran L, Masilamani M, Solomon S, Tikkanen R, Stuermer CA, Plattner H, Illges H. Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8241-6.
    [Show full text]
  • And Post-Translationally N-Myristoylated Proteomes in Human Cells
    ARTICLE Received 5 Mar 2014 | Accepted 5 Aug 2014 | Published 26 Sep 2014 DOI: 10.1038/ncomms5919 OPEN Global profiling of co- and post-translationally N-myristoylated proteomes in human cells Emmanuelle Thinon1,2,*,w, Remigiusz A. Serwa1,*, Malgorzata Broncel1, James A. Brannigan3, Ute Brassat1,2,w, Megan H. Wright1,4,w, William P. Heal1,w, Anthony J. Wilkinson3, David J. Mann2,4 & Edward W. Tate1,4 Protein N-myristoylation is a ubiquitous co- and post-translational modification that has been implicated in the development and progression of a range of human diseases. Here, we report the global N-myristoylated proteome in human cells determined using quantitative chemical proteomics combined with potent and specific human N-myristoyltransferase (NMT) inhibition. Global quantification of N-myristoylation during normal growth or apoptosis allowed the identification of 4100 N-myristoylated proteins, 495% of which are identified for the first time at endogenous levels. Furthermore, quantitative dose response for inhibition of N-myristoylation is determined for 470 substrates simultaneously across the proteome. Small-molecule inhibition through a conserved substrate-binding pocket is also demonstrated by solving the crystal structures of inhibitor-bound NMT1 and NMT2. The presented data substantially expand the known repertoire of co- and post-translational N-myristoylation in addition to validating tools for the pharmacological inhibition of NMT in living cells. 1 Department of Chemistry, Imperial College London, Exhibition Road, London SW7 2AZ, UK. 2 Department of Life Sciences, Imperial College London, Exhibition Road, London SW7 2AZ, UK. 3 York Structural Biology Laboratory, Department of Chemistry, University of York, York YO10 5DD, UK.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Targeting Multiple Genes Containing Long Mononucleotide A-T Repeats In
    Bhummaphan et al. J Transl Med (2021) 19:231 https://doi.org/10.1186/s12967-021-02902-6 Journal of Translational Medicine RESEARCH Open Access Targeting multiple genes containing long mononucleotide A-T repeats in lung cancer stem cells Narumol Bhummaphan1,2, Piyapat Pin‑on1,6,7, Preeyaporn Plaimee Phiboonchaiyanan2, Jirattha Siriluksana1, Chatchawit Aporntewan3,4, Pithi Chanvorachote2,5* and Apiwat Mutirangura1* Abstract Background: Intratumour heterogeneous gene expression among cancer and cancer stem cells (CSCs) can cause failure of current targeted therapies because each drug aims to target the function of a single gene. Long mononu‑ cleotide A‑T repeats are cis‑regulatory transcriptional elements that control many genes, increasing the expression of numerous genes in various cancers, including lung cancer. Therefore, targeting A‑T repeats may dysregulate many genes driving cancer development. Here, we tested a peptide nucleic acid (PNA) oligo containing a long A‑repeat sequence [A(15)] to disrupt the transcriptional control of the A‑T repeat in lung cancer and CSCs. Methods: First, we separated CSCs from parental lung cancer cell lines. Then, we evaluated the role of A‑T repeat gene regulation by counting the number of repeats in diferentially regulated genes between CSCs and the parental cells of the CSCs. After testing the dosage and efect of PNA‑A15 on normal and cancer cell toxicity and CSC pheno‑ types, we analysed genome‑wide expression to identify dysregulated genes in CSCs. Results: The number of A‑T repeats in genes diferentially regulated between CSCs and parental cells difered. PNA‑ A15 was toxic to lung cancer cells and CSCs but not to noncancer cells.
    [Show full text]
  • Supplementary Methods
    1 SUPPLEMENTARY METHODS 2 3 Antibodies 4 Monoclonal antibodies used were against transglutaminase 2 (TG2) (IA12, 5 University of Sheffield, UK; CUB 7402, MA5-12739 Invitrogen, UK), α-smooth 6 muscle actin (α-SMA) [1A4] (ab7817, Abcam, UK) and flotillin-2 (FLOT2) (610383, 7 BD Transduction Laboratories, UK). Polyclonal antibodies used were against 8 syndecan-4 (SDC4) (ab24511, Abcam, UK), TG2 (ab421, Abcam, UK), cyclophilin- 9 A (ab41684, Abcam, UK), β-Tubulin (ab6046, Abcam, UK), hemagglutinin (HA) 10 (C29F4, Cell Signaling Technology, UK) and GFP (ab290, Abcam, UK). 11 12 Unilateral ureteric obstruction 13 Experimental unilateral ureteric obstruction (UUO) was performed in TG2-KO and 14 control (Wild Type, WT) C57BL/6J mice as described by Vielhauer et al. (2001).1 15 To perform UUO, mice were anaesthetized with 5% isoflurane and anesthesia 16 maintained with 2% isoflurane during the surgical process. The left ureter of the 17 mice was obstructed using a legating clip (Hemoclip Plus, Weck Closure Systems). 18 ADEPT® [4% (w/v) icodextrin solution] was dispensed in the peritoneum to 19 prevent post-surgical adhesions prior to closing. The muscle wall was sealed with 20 continuous stitching and skin wound closed with interrupted stitching using 21 absorbable sutures. After the procedure, buprenorphine (0.1 mg/kg) was 22 administered to the mice for pain-relieving. Animal were allowed free access to 23 standard rodent chow and tap water. Mice were sacrificed and the left kidneys 24 harvested 21 days post-operation. All experimental procedures were carried out 25 under license in accordance with regulations laid down by Her Majesty’s 26 Government, UK (Animals Scientific Procedures Act ASPA, 1986), and were 1 27 approved by the University of Sheffield Animal Ethical Review Committee (ASPA 28 Ethical Review Process) and Nottingham Trent University Ethical Review 29 Committee (ASPA Ethical Review Process).
    [Show full text]
  • FLOT2 293 Cell Lysate Storage: Store at -80°C
    From Biology to Discovery™ FLOT2 293 Cell Lysate Storage: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored Subcategory: Cell Lysate at -20°C. Product is guaranteed 6 months from the date of Cat. No.: 401297 shipment. Unit: 0.1 mg For research use only, not for diagnostic or therapeutic Description: procedures. Antigen standard for flotillin 2 (FLOT2) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid (OriGene Technologies, Inc.) and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. Applications: ELISA, WB, IP Format: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). Alternate Names: Flotillin 2 (epidermal surface antigen 1); membrane component chromosome 17 surface marker 1; membrane component, chromosome 17, surface marker 1 (35kD protein identified by monoclonal antibody ECS-1); FLOT2; ECS-1; ECS1; ESA; ESA1; M17S1 Accession No.: NP_004466 Application Notes: WB: Mix equal volume of lysates with 2X SDS Loading Buffer.
    [Show full text]
  • Differential Interactome Proposes Subtype-Specific Biomarkers And
    Journal of Personalized Medicine Article Differential Interactome Proposes Subtype-Specific Biomarkers and Potential Therapeutics in Renal Cell Carcinomas Aysegul Caliskan 1,2,† , Gizem Gulfidan 1,† , Raghu Sinha 3,* and Kazim Yalcin Arga 1,* 1 Department of Bioengineering, Marmara University, Istanbul 34722, Turkey; [email protected] (A.C.); gizemgulfi[email protected] (G.G.) 2 Faculty of Pharmacy, Istinye University, Istanbul 34010, Turkey 3 Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA 17033, USA * Correspondence: [email protected] (R.S.); [email protected] (K.Y.A.) † These authors contributed equally to this work. Abstract: Although many studies have been conducted on single gene therapies in cancer patients, the reality is that tumor arises from different coordinating protein groups. Unveiling perturbations in protein interactome related to the tumor formation may contribute to the development of effective di- agnosis, treatment strategies, and prognosis. In this study, considering the clinical and transcriptome data of three Renal Cell Carcinoma (RCC) subtypes (ccRCC, pRCC, and chRCC) retrieved from The Cancer Genome Atlas (TCGA) and the human protein interactome, the differential protein–protein interactions were identified in each RCC subtype. The approach enabled the identification of dif- ferentially interacting proteins (DIPs) indicating prominent changes in their interaction patterns during tumor formation. Further, diagnostic and prognostic performances were generated by taking into account DIP clusters which are specific to the relevant subtypes. Furthermore, considering the mesenchymal epithelial transition (MET) receptor tyrosine kinase (PDB ID: 3DKF) as a potential Citation: Caliskan, A.; Gulfidan, G.; drug target specific to pRCC, twenty-one lead compounds were identified through virtual screening Sinha, R.; Arga, K.Y.
    [Show full text]